215 related articles for article (PubMed ID: 27384477)
1. Androgen receptor as potential therapeutic target in metastatic endometrial cancer.
Tangen IL; Onyango TB; Kopperud R; Berg A; Halle MK; Øyan AM; Werner HM; Trovik J; Kalland KH; Salvesen HB; Krakstad C
Oncotarget; 2016 Aug; 7(31):49289-49298. PubMed ID: 27384477
[TBL] [Abstract][Full Text] [Related]
2. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
Cochrane DR; Bernales S; Jacobsen BM; Cittelly DM; Howe EN; D'Amato NC; Spoelstra NS; Edgerton SM; Jean A; Guerrero J; Gómez F; Medicherla S; Alfaro IE; McCullagh E; Jedlicka P; Torkko KC; Thor AD; Elias AD; Protter AA; Richer JK
Breast Cancer Res; 2014 Jan; 16(1):R7. PubMed ID: 24451109
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival.
Kamal AM; Bulmer JN; DeCruze SB; Stringfellow HF; Martin-Hirsch P; Hapangama DK
Br J Cancer; 2016 Mar; 114(6):688-96. PubMed ID: 26930451
[TBL] [Abstract][Full Text] [Related]
4. Androgen Receptor Expression in Endometrial Carcinoma.
Zadeh SL; Duska LR; Mills AM
Int J Gynecol Pathol; 2018 Mar; 37(2):167-173. PubMed ID: 28582344
[TBL] [Abstract][Full Text] [Related]
5. Expression of androgen receptor splice variants in clinical breast cancers.
Hickey TE; Irvine CM; Dvinge H; Tarulli GA; Hanson AR; Ryan NK; Pickering MA; Birrell SN; Hu DG; Mackenzie PI; Russell R; Caldas C; Raj GV; Dehm SM; Plymate SR; Bradley RK; Tilley WD; Selth LA
Oncotarget; 2015 Dec; 6(42):44728-44. PubMed ID: 26554309
[TBL] [Abstract][Full Text] [Related]
6. Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions.
Tangen IL; Werner HM; Berg A; Halle MK; Kusonmano K; Trovik J; Hoivik EA; Mills GB; Krakstad C; Salvesen HB
Eur J Cancer; 2014 Nov; 50(17):3003-10. PubMed ID: 25281525
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future anti-androgen therapy in endometrial cancers.
Moatamed NA; Vahdatshariatpanahi S; Gjertson DW; Sachs CR; Kang Y; Ostrzega N; Huang J; Memarzadeh S
PLoS One; 2023; 18(9):e0291361. PubMed ID: 37725629
[TBL] [Abstract][Full Text] [Related]
8. Molecular Modifiers of Hormone Receptor Action: Decreased Androgen Receptor Expression in Mismatch Repair Deficient Endometrial Endometrioid Adenocarcinoma.
Gan Q; Crumley S; Broaddus RR
Int J Gynecol Pathol; 2019 Jan; 38(1):44-51. PubMed ID: 29210800
[TBL] [Abstract][Full Text] [Related]
9. Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions.
Tangen IL; Veneris JT; Halle MK; Werner HM; Trovik J; Akslen LA; Salvesen HB; Conzen SD; Fleming GF; Krakstad C
Gynecol Oncol; 2017 Dec; 147(3):672-677. PubMed ID: 28927900
[TBL] [Abstract][Full Text] [Related]
10. Investigation of hormone receptor expression and its prognostic value in endometrial stromal sarcoma.
Park JY; Baek MH; Park Y; Kim YT; Nam JH
Virchows Arch; 2018 Jul; 473(1):61-69. PubMed ID: 29869299
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis-related proteins and steroid hormone receptors in normal, hyperplastic, and neoplastic endometrium.
Bozdoğan O; Atasoy P; Erekul S; Bozdoğan N; Bayram M
Int J Gynecol Pathol; 2002 Oct; 21(4):375-82. PubMed ID: 12352186
[TBL] [Abstract][Full Text] [Related]
12. Expression of androgen receptors in benign and malignant endometrial stromal neoplasms.
Moinfar F; Regitnig P; Tabrizi AD; Denk H; Tavassoli FA
Virchows Arch; 2004 May; 444(5):410-4. PubMed ID: 15007645
[TBL] [Abstract][Full Text] [Related]
13. The androgen receptor antagonist enzalutamide induces apoptosis, dysregulates the heat shock protein system, and diminishes the androgen receptor and estrogen receptor β1 expression in prostate cancer cells.
Abazid A; Martin B; Choinowski A; McNeill RV; Brandenburg LO; Ziegler P; Zimmermann U; Burchardt M; Erb H; Stope MB
J Cell Biochem; 2019 Oct; 120(10):16711-16722. PubMed ID: 31297844
[TBL] [Abstract][Full Text] [Related]
14. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
15. Changes in expression of estrogen receptors alpha and beta in relation to progesterone receptor and pS2 status in normal and malignant endometrium.
Saegusa M; Okayasu I
Jpn J Cancer Res; 2000 May; 91(5):510-8. PubMed ID: 10835496
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
17. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
[TBL] [Abstract][Full Text] [Related]
18. Expression profile and prognostic role of sex hormone receptors in gastric cancer.
Gan L; He J; Zhang X; Zhang YJ; Yu GZ; Chen Y; Pan J; Wang JJ; Wang X
BMC Cancer; 2012 Dec; 12():566. PubMed ID: 23199240
[TBL] [Abstract][Full Text] [Related]
19. Switch in FOXA1 status associates with endometrial cancer progression.
Tangen IL; Krakstad C; Halle MK; Werner HM; Oyan AM; Kusonmano K; Petersen K; Kalland KH; Akslen LA; Trovik J; Hurtado A; Salvesen HB
PLoS One; 2014; 9(5):e98069. PubMed ID: 24849812
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
